Related Experiment Video
Updated: Apr 27, 2026
11:02
Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics
Published on: November 29, 2024
1.4K
Metabolomics in pediatric nephrology: emerging concepts
Mina H Hanna1, Patrick D Brophy
1Department of Pediatrics, University of Kentucky, Lexington, KY, USA.
Pediatric Nephrology (Berlin, Germany)
|July 17, 2014
Summary
Metabolomics, the study of metabolites, offers new ways to monitor kidney function and find novel biomarkers for kidney diseases. This approach provides insights into disease mechanisms and potential therapeutic targets in pediatric nephrology.
Area of Science:
- Analytical Biochemistry
- Systems Biology
Background:
- Metabolomics systematically studies metabolite changes in biological samples.
- Metabolites reflect an organism's phenotype, offering insights into genome, transcriptome, and proteome expression.
- Metabolomics is an emerging field with potential in monitoring kidney function and detecting renal events.
Purpose of the Study:
- To highlight the potential of metabolomics in pediatric nephrology.
- To explore the use of metabolomics for biomarker discovery and understanding disease mechanisms.
- To investigate the interplay of environmental and genetic factors in kidney diseases.
Main Methods:
- Systematic study of metabolites and their alterations in biological samples.
- Analysis of small molecule metabolites for mechanistic insights.
- Application of metabolomic approaches in the context of pediatric kidney diseases.
Main Results:
- Metabolites closely reflect the phenotype of an organism.
- Metabolomics can provide mechanistic insights into novel kidney disease biomarkers.
- Identified limitations of current traditional kidney disease markers.
Conclusions:
- Metabolomics holds significant potential for real-time kidney function monitoring and adverse event detection.
- It aids in discovering novel biomarkers and therapeutic targets in pediatric nephrology.
- Offers a unique window into environmental/genetic interactions in specific kidney disease states.
Related Concept Videos
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
405
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
405
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
400
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
400
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
954
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
954
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
324
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
324
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
271
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
547
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
547